HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

https://doi.org/10.1007/s10156-005-0385-ZGet rights and content

Abstract

A 51-year-old man who was hepatitis B surface antigen (HBsAg)-negative and positive for anti-hepatitisB surface antigen (anti-HBs) and anti-hepatitis B core antigen (anti-HBc), during rituximab therapy for chronic Lymphocytic leukemia, developed reactivation of hepatitisB virus (HBV) infection with hepatitis that proceededtowards hepatic failure and death in spite of lamivudine therapy. HBsAg remained persistently negative, notwithstanding a high HBV-DNA titer. Our observation, following other cases of fatal reactivation of HBV infection in patients receiving rituximab, suggests that, in all patients with previous markers of HBV infection, lamivudine prophylaxis should be considered during rituximab therapy.

References (14)

There are more references available in the full text version of this article.

Cited by (113)

  • Management of chemotherapy-induced hepatitis B virus reactivation

    2012, Journal of the Chinese Medical Association
View all citing articles on Scopus
View full text